[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Galland et al., 2021 - Google Patents

Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic non small cell lung cancer

Galland et al., 2021

View HTML
Document ID
2105628159608435715
Author
Galland L
Lecuelle J
Favier L
Fraisse C
Lagrange A
Kaderbhai C
Truntzer C
Ghiringhelli F
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Monoclonal antibodies targeting PD1/PD-L1 are game changers in the treatment of advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01—Social networking
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means

Similar Documents

Publication Publication Date Title
Wu et al. Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: a longitudinal, prospective trial
Vitiello et al. Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): a single institution experience
Zheng et al. Development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile
Liao et al. The clinical utility of the geriatric nutritional risk index in predicting postoperative complications and long-term survival in elderly patients with colorectal cancer after curative surgery
Galland et al. Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic non small cell lung cancer
Prelaj et al. Machine learning using real-world and translational data to improve treatment selection for NSCLC patients treated with immunotherapy
Gong et al. Cachexia index as a prognostic indicator in patients with gastric cancer: a retrospective study
Choi et al. Diagnostic and prognostic roles of CDX2 immunohistochemical expression in colorectal cancers
Lindenmann et al. Prediction of postoperative clinical outcomes in resected stage I non-small cell lung cancer focusing on the preoperative Glasgow Prognostic Score
Han et al. Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: an analysis of a prospectively immunoprofiled cohort
Chidharla et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis
Su et al. Identification and validation of the prognostic panel in clear cell renal cell carcinoma based on resting mast cells for prediction of distant metastasis and immunotherapy response
Wu et al. Chromosomal instability may not be a predictor for immune checkpoint inhibitors from a comprehensive bioinformatics analysis
Turri et al. Clinical significance of preoperative inflammatory markers in prediction of prognosis in node-negative colon cancer: correlation between neutrophil-to-lymphocyte ratio and poorly differentiated clusters
Kim et al. Impact of comorbidities, sarcopenia, and nutritional status on the long-term outcomes after endoscopic submucosal dissection for early gastric cancer in elderly patients aged≥ 80 years
Mou et al. Clinical and prognostic value of PPIA, SQSTM1, and CCL20 in hepatocellular carcinoma patients by single-cell transcriptome analysis
Formica et al. Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases
Alsalman et al. Associations of Complete Blood Count parameters with Disease-Free Survival in Right-and left-sided colorectal Cancer patients
Tankyevych et al. Development of radiomic-based model to predict clinical outcomes in non-small cell lung cancer patients treated with immunotherapy
Yamai et al. Utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice
Sorroche et al. PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in Brazil
Brocco et al. High blood concentration of leukocyte-derived extracellular vesicles is predictive of favorable clinical outcomes in patients with pancreatic cancer: Results from a multicenter prospective study
Itonaga et al. Kras gene analysis using liquid-based cytology specimens predicts therapeutic responses and prognosis in patients with pancreatic cancer
Samir et al. Transcription factor MAFB as a prognostic biomarker for the lung adenocarcinoma
Kang et al. Clinicopathological significances of tumor–stroma ratio (TSR) in colorectal cancers: Prognostic implication of TSR compared to hypoxia-inducible factor-1α expression and microvessel density